Interpatient variability in exposure to certain chemotherapy agents can influence patient outcome, particularly with high-dose chemotherapy. We evaluated the possibility of a pharmacokinetic (PK) drug-drug interaction between the antiemetic agents and highdose cyclophosphamide, cisplatin and BCNU (CPA/cDDP/BCNU). Twenty-three self-selected patients treated with high-dose CPA/cDDP/BCNU followed by autologous hematopoietic progenitor cell support (AHPCS) received ondansetron, lorazepam and diphenhydramine as antiemetics. PK parameters for each chemotherapeutic drug in the regimen were compared with those of 129 patients who received exactly the same chemotherapy but an antiemetic regimen substituting prochlorperazine for ondansetron. In addition, we performed a review of the English literature for reported drug-drug interactions between antiemetics and chemotherapy agents that led to modifications in any PK parameters of the chemotherapy agent. Our retrospective study showed that the mean area under the curve (AUC) for both cyclophosphamide (76 600 vs 90 600 g/ml/min, P = 0.001) and cisplatin (525 vs 648 g/ml/min, P = 0.01) were significantly lower in the ondansetron group when compared with the prochlorperazine group. The AUC for BCNU was not significantly different in both groups (544 vs 677, P = 0.43). We found only one report of modifications of the PK parameters of high-dose chemotherapy agents due to drug-drug interactions with the most commonly used antiemetics in a review of the English literature between 1966 and 1995. We concluded that the AUC of high-dose cyclophosphamide and cisplatin are significantly lower when ondansetron, as opposed to prochlorperazine, is used as the antiemetic. The small sample size and heterogeneity of this group of patients precludes any outcome analysis of pharmacodynamic endpoints such as toxicity or antitumor effect. Nevertheless, the potential for interactions between antiemetics and chemotherapy agents should be taken into account when using different high-dose chemotherapy regimens.
High-dose chemotherapy with autologous hematopoietic progenitor cell support (AHPCS) is a treatment option for selected patients with high-risk or relapsed malignancies. 1 Over the past several years the morbidity and mortality of the procedure has markedly decreased, but it is still associated with significant toxicity from the preparative regimens. 2 We and others have shown that interpatient variability in drug exposure as measured by pharmacokinetic (PK) parameters of some drugs used in high-dose chemotherapy correlate with the toxicity and effectiveness of the treatment. Examples of these toxicities are BCNU-induced lung injury, 3 busulfan-induced veno-occlusive disease of the liver, 4 cyclophosphamide cardiotoxicity, 5 and polyneuropathy and mucositis secondary to paclitaxel. 6 Also, in the study of CPA cardiotoxicity, the PK of CPA was correlated with the median duration of response after high-dose chemotherapy. 5 Since drug PK may correlate with outcome, the potential for drug-drug interactions between the chemotherapy agents and the drugs used for supportive care should not be ignored, particularly if such interactions can substantially modify the PK of the chemotherapeutic drugs. Strikingly, only one study could be found in the literature which studied the potential for drug-drug interactions between chemotherapy and antiemetics given to patients who undergo high-dose chemotherapy. 7 This is particularly noticeable since antiemetics are always given in close proximity to chemotherapy.
The CPA/cDDP/BCNU regimen was developed with the use of infusional prochlorperazine and intermittent diphenhydramine and lorazepam for antiemesis. 8 This antiemetic regimen was continued without change because of its effectiveness and to avoid changes in scientific design. Once the serotonin-antagonist class of antiemetics became available and appeared to offer improved antiemesis, 9 certain patients demanded ondansetron as antiemetic treatment. Pharmacokinetic data from these patients formed the basis for this study. 10 We report here the findings of such a study together with the findings of a review of the English literature on the subject.
Patients and methods

Patients
Between July 1992 and November 1993, 23 patients receiving ondansetron were self-selected from among those enrolled in phase II studies who were to receive high-dose chemotherapy with cyclophosphamide, cisplatin, and BCNU as described by Peters et al. 11 Demographics are summarized in Table 1 . One hundred and twenty-nine contemporaneously treated patients who received an identical high-dose chemotherapy regimen but with prochlorperazine instead of ondansetron as antiemetic were used as controls.
All patients had a Southwest Oncology Group (SWOG) performance status of Ͻ2 and acceptable organ function prior to high-dose chemotherapy (creatinine clearance Ͼ60 ml/min, left ventricular ejection fraction Ͼ45%, DLCO and FEV 1.0 Ͼ60% of predicted and bilirubin/SGOT/SGPT Ͻ2 times the upper limit of normal). Patients were treated under protocols approved by the Institutional Review Board of the University of Colorado Health Sciences Center and written informed consent was obtained from all patients.
Treatment Regimen
Supportive care and antiemetics: Uniform supportive care measures were used. All study patients received ondansetron 8 mg i. 
Stem cell collection:
All patients underwent a bone marrow harvest under general anesthesia. The bone marrow was frozen and stored using previously described procedures. 12 Peripheral blood progenitor cells (PBPCs) were mobilized, collected, processed and cryopreserved as previously described. 12 The bone marrow, the PBPC or both were used to reconstitute hematopoiesis.
High-dose chemotherapy:
Patients were admitted to the University of Colorado Bone Marrow Transplant Unit on day −7, where vigorous intravenous hydration sufficient to ensure a urinary output Ͼ200 ml/h, and continuous bladder irrigation were initiated. All doses of chemotherapy were calculated on the actual patient body weight unless the actual weight was у20% over the ideal body weight, in which case the average of the actual and ideal weight was used to calculate the body surface area. On day −6, cisplatin 165 mg/m 2 was started and administered as a 72 h i.v. continuous infusion. Cyclophosphamide 1875 mg/m 2 /day was administered as a 1 h i.v. infusion on days −6, −5 and −4. Immediately after the cisplatin infusion was completed, BCNU 600 mg/m 2 was given i.v. over 2 h. Cyclophosphamide, cisplatin and BCNU were formulated and infused as previously reported. 3 The doses of all three drugs were given as planned to every patient both in the study and control groups.
Regimen-related toxicity grading
Toxicities were scored daily using SWOG toxicity criteria. All the toxicity scores were stored in a computer data base for later analysis (TMR).
Pharmacology
Blood sampling schedule and analysis were identical for both groups of patients. Cyclophosphamide, cisplatin and BCNU concentrations were monitored and analyzed as previously described. 3 Blood samples for cyclophosphamide were obtained in heparinized tubes at 30, 60, 90, 120, 180, 300, 420, 540, 780, 1020 and 1260 min after the start of the infusion. They were stored at 4°C and analyzed within 24 h using the method of El-Yazigi and Martin. 13 Blood samples for cisplatin were obtained at 30, 60 min, and 3, 24, 25, 26, 48, 49, 50 and 70 h from the initiation of the infusion. Samples were placed in a 10 cm 3 heparin-containing tube and processed immediately. Plasma was ultrafiltrated using an Amicon Centrifree Micropartition Systems (Millipore, Bedford, MA, USA) tube and stored at −20°C until analysis. Blood samples for BCNU were obtained at 30 min after the start of the infusion, at the mid-infusion point, at the end of the infusion, and at 15, 30, 45, 60, 90, 120, 240 min after completion of the infusion. Samples were collected in a 10 ml air evacuated heparinized tube containing 3 ml of HPLC-grade ethyl acetate (Burdick and Jackson Laboratories, Muskegon, MI, USA) spiked with 50 g/ml of diphenylhydantoin (Sigma Chemical, St Louis, MO, USA). Exactly 3 ml of whole blood were injected in each tube and the contents were vortexed for 20 s at the bedside. The tubes were protected from light and stored at 4°C. Samples were analyzed within 24 h. The CPA, cDDP and BCNU concentration and sample time data were used for calculation of the following derived PK parameters: maximal concentration (Cmax), area under the time concentration curve (AUC) and half-life (t 1/2 ). PC NONLIN software was used to perform the analysis. Model 2 from PCNONLIN, a one-compartment model with constant intravenous input and first order output was used for BCNU. The Gauss-Newton algorithm with the Levenberg modification was used for data convergence. Model 10, a twocompartment model with constant intravenous input and first order output, was used for cyclophosphamide. The Nelder-Mead algorithm was used for convergence of the data. Adequate data sets for PK analysis of CPA, cDDP and BCNU were available in 23, 23 and 19 patients, respectively, in the study group. Incomplete data resulted from technical difficulties obtaining adequate blood samples from four patients. Adequate data sets for PK analysis of CPA, cDDP, BCNU were available in 129, 87, 107 patients in the control group, respectively. As with the study group, incomplete data resulted from technical diffi-culties obtaining adequate blood samples from the remaining patients.
Statistical analysis
The derived PK parameters in the ondansetron group (OND) were compared with those of historical controls (control group or PRO). Comparisons were made using the rank sum test (Statgraphics).
Literature search
A search of the English literature between 1966 and 1995 was performed using OVID. The following key words were used: ondansetron, granisetron, metoclopramide and prochlorperazine. These terms were combined with: pharmacokinetics, interactions, drug-drug interactions and pharmacology.
Results
Pharmacokinetics
The mean area under the curve (AUC) for cDDP and CPA for the 23 patients in the OND group were 525 g/ml/min and 76 600 g/ml/min, respectively compared with 648 g/ml/min and 90 600 g/ml/min, respectively for the PRO group (129 patients for CPA and 87 patients for cDDP). In both cases the differences are statistically significant (P = 0.01 for cDDP and P = 0.001 for CPA, Table 2 ). The AUC for BCNU was not statistically different in both groups (OND = 544 g/ml/min vs PRO = 677 g/ml/min, P = 0.43). We also compared the elimination half-life (t 1/2 ) and peak concentration (Cmax) for all three drugs and found that only the t 1/2 for CPA on day 2 of administration and Cmax of CPA on day 3 of administration were significantly lower for the OND group. Selected pharmacokinetic parameters are summarized in Table 2 .
Toxicity
The small sample size and the heterogeneity of the group of patients treated with ondansetron precluded any statistical analysis of toxicity. There were six patients with grade 3- 4 toxicities in the OND group. All these patients developed pulmonary toxicity (incidence 26%); two of them also had renal toxicity, and one experienced liver toxicity in addition to the pulmonary toxicity.
Literature search
Only one report of a modification of a pharmacokinetic parameter of a chemotherapy drug by selected antiemetics was found using the above defined strategies. In that study, Gilbert et al 7 described the difference in PK of high-dose cyclophosphamide depending on whether prochlorperazine or ondansetron are administered as antiemetics. Also, one report referred to change in the PK of the antiemetic drug due to the chemotherapy agent administered.
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Discussion
We have shown that the AUC of cDDP and CPA varies significantly between groups of patients receiving OND and PCP as antiemetics. The small number of patients, together with the fact that this was a heterogenous group precluded meaningful statistical analysis of toxicity and/or response compared to drug PK, although it does not rule out potential differences.
Ondansetron 15 and PCP are metabolized in the liver by the P-450 system, as is CPA. CPA is primarily metabolized by P450 2B and 3A, 16, 17 and ondansetron primarily by P450 1A2.
18 An interaction at the P450 level which might explain the PK data described here seems unlikely but cannot be ruled out. cDDP is known, in animal models, to affect P-450 mRNA expression, therefore modifying its activity. 19 An interaction at the level of protein binding or renal tubular secretion is also possible. The fact that similar results have recently been reported by others, as summarized in Table 2 , adds strength to our findings. 7 Furthermore, the AUC differences of CPA in this other study are virtually identical to those reported here.
Chemotherapy agents have a very narrow therapeutic index, so small differences in drug exposure can be reflected in dramatic differences in both toxicity and response. This becomes even more significant in the highdose chemotherapy setting when the drugs are routinely given at doses that are maximally toxic in an attempt to overcome tumor resistance. A difference in drug exposure of 15%, like the one reported here for CPA, could have major implications in terms of response and toxicity but be undetectable without a large randomized trial.
Considering this information, it is surprising that so little effort has been devoted to the study of drug-drug interactions involving chemotherapy agents among themselves and with the supportive care medications. In our literature search of the last 29 years we found only one report of drug-drug interactions involving ondansetron, granisetron, prochlorperazine or metoclopramide in which the PK of any high-dose chemotherapy agent is modified. 7 Antiemetics are among the most widely used medication in oncology, both with conventional and high-dose chemotherapy. The results of this pilot study, together with the data generated by Gilbert et al, 7 suggest that more attention should be paid to these potential interactions. Furthermore, we propose that investigators should report the supportive care medications used with conventional dose chemotherapy and particularly with high-dose chemotherapy, and that this component of therapy should be standardized whenever possible.
